AUPH Aurinia Pharmaceuticals Inc

+0.26  (+5%)
Previous Close 5.64
Open 5.68
Price To Book 4.24
Market Cap 541,578,700
Shares 91,829,758
Volume 691,362
Short Ratio
Av. Daily Volume 457,866

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 trial to be initiated 4Q 2019.
Voclosporin Ophthalmic Solution (VOS)
Dry eye syndrome
Phase 2 interim data due 2020.
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Phase 3 data due 4Q 2019.
Voclosporin - AURORA
Phase 2 trial enrollment has commenced - noted June 25, 2018.
Voclosporin - AURORA 2

Latest News

  1. An Example of How I Stalk a Trade
  2. Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates
  3. Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights
  4. Will Aurinia Pharmaceuticals (AUPH) Report Negative Q2 Earnings? What You Should Know
  5. Aurinia- From Dry Eye to Lupus Nephritis
  6. Aurinia Announces Further Strengthening of the Senior Management Team
  7. ILJIN Comments on Aurinia Pharmaceutical’s Annual Meeting
  8. Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting
  9. ILJIN Chairman Issues Open Letter to Aurinia Shareholders
  10. Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline
  11. As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia’s Full Potential
  12. Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia’s Director Nominees
  13. ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts
  14. ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information
  15. Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
  16. Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders
  17. Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders
  18. Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
  19. Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss
  20. Aurinia: 1Q Earnings Snapshot